A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).

Trial ID # NCT03737643; DUO-O
Phase III
Drug Class DNA Damage Repair Pathway Inhibitors: PARP
Drug Name Olaparib
Alternate Drug Names AZD2281, Lynparza
Drugs in Trial Bevacizumab, Carboplatin, Durvalumab, Olaparib, Paclitaxel
Eligible Participant

Newly diagnosed stage III/IV high grade non-gBRCA MUT ovarian cancer (neo-adjuvant or adjuvant and maintenance)

Patients Enrolled

1130

Therapy Setting

First-line

Study Design

Double Blind, Randomized

Endpoints

PFS, OS, evaluated per RECIST

Biomarkers

tBRCA status, Exploratory: HRD status

Efficacy

CarboPt+Pac+Bev+Dur w/Bev+Dur+Ola maint vs CarboPt+Pac+Bev+Dur w/ Bev+Dur+Ola Placebo maint (n= 374) vs CarboPt+Pac+Bev+Dur Placebo w/ Bev+Dur placebo (n=378) +Ola Placebo maint:

ITT (excl. BRCA MUT):
PFS: 25.1 vs 20.6 vs 19.3 months; HR: 0.61 (0.51-0.73, p<0.0001); HR: 0.87 (0.74-1.03, p=0.11)
24 months PFS: 53.0 vs 38.7 vs 33.2%
OS: 48.5 vs NR vs 48.0 months; HR: 0.95 (0.76-1.20, p=0.68); HR: 0.92 (0.73-1.16)
24 months OS: 83.3 vs 81.2 vs 79.8%
HRD+ (excl. BRCA MUT):
PFS: 45.1 vs 25.1 vs 23.3 months; HR: 0.46 (0.33-0.65, p<0.0001); HR: 0.89 (0.67-1.19)
24 months PFS: 72.9 vs 50.9 vs 46.5%
OS: NR vs NR vs NR; HR: 0.84 (0.51-1.37); HR: 0.69 (0.41-1.15)
24 months OS: 96.4 vs 91.7 vs 88.6%

Exploratory analysis; HRD-:
PFS: 21.1 vs 15.4 vs 17.5 months; HR: 0.68 (0.54-0.85); HR: 0.92 (0.74-1.14)
24 months PFS: 41.1 vs 30.9 vs 26.1%
OS: 41.1 vs 30.9 vs 26.1 months; HR: 0.99 (0.76-1.31); HR: 1.05 (0.80-1.38)
24 months OS: 76.4 vs 73.0 vs 76.9%

Clinically Significant Adverse Events

CarboPt+Pac+Bev+Dur w/Bev+Dur+Ola maint vs CarboPt+Pac+Bev+Dur w/ Bev+Dur+Ola Placebo maint (n= 374) vs CarboPt+Pac+Bev+Dur Placebo w/ Bev+Dur placebo (n=378) +Ola Placebo maint:
Serious AE: overall (39 vs 43 vs 34%); MDS/AML: (2 vs 0 vs 1)
Grade 3-4 AE: overall (71 vs 66 vs 61%); neutropenia (31 vs 28 vs 26%); anemia (24 vs 8 vs 8%)

Conclusion

CarboPt+Pac+Bev+Dur followed by maintenance Bev+Dur+Ola in patients with newly diagnosed non-tBRCAm advanced OC resulted in a statistically significant and clinically meaningful improvement in PFS vs CarboPt+Pac+Bev followed by maintenance Bev. Safety was generally consistent with the known profiles of each agent

Reference

Harter P et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. J Clin Oncol 41, 2023 (suppl 17; abstr LBA5506)
https://ascopubs.org/doi/10.1200/JCO.2023.41.17_suppl.LBA5506

Harter P et al. Slide from presentation
https://www.clearityfoundation.org/wp-content/uploads/2023/08/DUO-O-slide-ASCO-2023.pdf

Harter P et al. Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: Updated results from DUO-O/ENGOT-OV46/GOG-3025 Trial. SGO (2024)
https://www.clearityfoundation.org/wp-content/uploads/2024/05/Harter-et-al.-DUO-O-SGO-2024.pdf

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.